MEK1 mutations confer resistance to MEK and B-RAF inhibition

Genetic alterations that activate the mitogen-activated protein kinase (MAP kinase) pathway occur commonly in cancer. For example, the majority of melanomas harbor mutations in the BRAF oncogene, which are predicted to confer enhanced sensitivity to pharmacologic MAP kinase inhibition (e.g., RAF or...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Emery, Caroline M., Vijayendran, Krishna G., Zipser, Marie C., Sawyer, Allison M., Niu, Lili, Kim, Jessica J., Hatton, Charles, Chopra, Rajiv, Oberholzer, Patrick A., Karpova, Maria B., MacConaill, Laura E., Zhang, Jianming, Gray, Nathanael S., Sellers, William R., Dummer, Reinhard, Garraway, Levi A.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2009
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2777185/
https://ncbi.nlm.nih.gov/pubmed/19915144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0905833106
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados